NVAX — NOVAVAX INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1000694 ·
Last close
$11.01
Market Cap
$1.82B
52W High
$13.39
52W Low
$6.20
ADV30
6,761,577
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 56,698,000 | 42,452,000 | -54,906,000 | -53,387,000 | 955,575,000 | 191,458,000 | 1,146,282,000 |
| Mar 2026 | 139,514,000 | 108,819,000 | -15,430,000 | -9,491,000 | 1,043,162,000 | 228,363,000 | 1,187,924,000 |
| Dec 2025 | 147,139,000 | 125,035,000 | 15,037,000 | 17,527,000 | 1,176,512,000 | 240,634,000 | 1,304,265,000 |
| Sep 2025 | 70,445,000 | 48,949,000 | -80,980,000 | -202,379,000 | 1,179,889,000 | 268,023,000 | 1,336,561,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,556,000
Investing CF
$-33,309,000
Financing CF
$72,473,000
CapEx
$-6,063,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,631,026,000
Inventory
$10,006,000
Receivables
$18,739,000
ST Investments
$527,882,000
EBIT TTM
$-223,419,000
Pretax Income TTM
$-245,315,000
Interest Exp TTM
$21,896,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$413,796,000
EBITDA
$-101,552,000
Free Cash Flow
$153,394,432
Enterprise Value
$1,131,767,680
Total Cash
$719,340,032
Total Debt
$297,319,008
Shares Out
164,945,726
Trailing EPS
$-1.53
Book Value
$-1.16
ROE
—
ROA
-6.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,479,000 | 550,640,000 | 440,302,000 | 1,176,512,000 | 1,304,265,000 | -127,753,000 | -244,635,000 |
| Dec 2024 | 682,162,000 | -248,931,000 | -187,499,000 | 1,560,418,000 | 2,184,259,000 | -623,841,000 | -87,263,000 |
| Dec 2023 | 556,382,000 | -566,511,000 | -545,062,000 | 1,797,490,000 | 2,514,417,000 | -716,927,000 | -713,967,000 |
| Dec 2022 | 1,598,951,000 | -644,736,000 | -657,939,000 | 2,258,679,000 | 2,892,757,000 | -634,078,000 | -415,937,000 |
TTM Snapshot
Revenues TTM
$596,338,000
NetIncome TTM
$-87,835,000
OpCashFlow TTM
—
Assets (Latest)
$1,043,162,000
Forward EPS
$-0.61
Max Pain — expiry 2026-10-16
max pain strike: $9.50 · spot: $12.59 · call oi: 35,764 · put oi: 8,842Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $1.80B | $1.39 | — |
| MESO | MESOBLAST LTD | $1.79B | $13.75 | — |
| VIR | Vir Biotechnology, Inc. | $1.88B | $11.12 | — |
| ALVO | Alvotech | $2.02B | $5.67 | — |
| VCEL | Vericel Corp | $2.05B | $40.05 | — |
News headlines (Yahoo Finance, 1h cache)
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
2026-10-09 12:00 · Yahoo
Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade
2026-10-08 17:18 · Yahoo
Should Novavax’s Headline-Driven Volatility Around Russia Health Scare Require Action From NVAX Investors?
2026-10-08 15:16 · Yahoo
Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility
2026-10-07 10:26 · Yahoo
Novavax, Moderna stocks fall after WHO calls plague risk 'low'
2026-10-06 15:59 · Yahoo
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
2026-10-06 20:45 · Yahoo
Novavax Sinks 12% as WHO Calls Plague Risk “Very Low”
2026-10-06 19:21 · Yahoo
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher
2026-10-06 13:56 · Yahoo
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
2026-10-06 06:13 · Yahoo
NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
2026-10-06 03:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.